Skip to main content

Elevance Health to Hold Conference Call and Webcast to Discuss Third Quarter Results on October 19, 2022

Elevance Health (NYSE: ELV) will release third quarter 2022 financial results on October 19, 2022, at 6:00 a.m. Eastern Daylight Time (“EDT”). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers:

888-947-9963 (Domestic)

800-813-5525 (Domestic Replay)

312-470-0178 (International)

203-369-3346 (International Replay)

The access code for the call is 3972058. There is no access code for the replay. The replay will be available from 11:30 a.m. EDT on October 19, 2022 until the end of the day on November 18, 2022. The call will also be available through a live webcast at www.elevancehealth.com under the “Investors” link. A webcast replay will be available following the call.

About Elevance Health, Inc.

Elevance Health is a lifetime, trusted health partner fueled by its purpose to improve the health of humanity. The company supports consumers, families, and communities across the entire care journey – connecting them to the care, support, and resources they need to lead healthier lives. Elevance Health’s companies serve more than 118 million people through a diverse portfolio of industry-leading medical, digital, pharmacy, behavioral, clinical, and complex care solutions. For more information, please visit www.elevancehealth.com or follow us @ElevanceHealth on Twitter and Elevance Health on LinkedIn.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.94
+0.40 (0.18%)
AAPL  273.26
-0.85 (-0.31%)
AMD  208.14
+0.56 (0.27%)
BAC  55.30
-0.03 (-0.06%)
GOOG  310.19
+0.88 (0.28%)
META  651.86
+4.35 (0.67%)
MSFT  473.98
-0.84 (-0.18%)
NVDA  176.78
+0.49 (0.28%)
ORCL  186.11
+1.19 (0.64%)
TSLA  477.95
+2.64 (0.56%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.